Interleukin-1 (IL-1) is a major proinflammatory cytokine produced by monocytes/macrophages. At the inflammatory site, IL-1 is a potent inducer of the production of prostaglandin E2 (PGE2) and metalloproteinases on fibroblast-like cells, thus triggering tissue damage. The biological activity of IL-1 is counterbalanced by two types of inhibitors: the IL-1 receptor antagonist (IL-lRa) which competitively binds IL-1 receptor without inducing signal transduction; and IL-1 soluble receptors (IL-lsR) which bind IL-1 and diminish the free concentration of soluble cytokine, thus hampering its binding to the cell surface receptor. Since ILlsR can also bind IL-lRa, we studied the simultaneous effects of both inhibitors on the production of interstitial collagenase (C'ase) and PGE2 by human dermal fibroblasts and synovial cells stimulated by either IL-la or IL-1,8. IL-lRa inhibited fibroblast and synovial cell stimulation by s 90%, with the exception of C'ase production by synovial cells which was inhibited by -55%. Type I IL-lsR (IL-lsRI) preferentially inhibited IL-la, whereas type II IL-lsR (ILlsRII) mainly inhibited IL-1,8. When IL-lRa was used simultaneously with IL-lsRI, the final inhibition was lower than that of either of the inhibitors. The simultaneous presence of IL-lRa and IL-lsRIl abolished the IL-1-induced production of PGE2 and C'ase on both dermal fibroblasts and synovial cells, demonstrating that concurrently these two inhibitors are able to abolish most of the inflammatory response. To our knowledge, this is the first example of two types of inhibitors that abolish each other's effects, one of which acts at the receptor level and the other at the ligand level, thus leaving ligand activity unimpaired. (J. Clin. Invest. 1995. 96:38-41.) Key words: interleukin-1 * interleukin-i receptor antagonist * interleukin-1 soluble receptors synovial cells -metalloproteinases
Introduction
The multifunctional cytokine IL-1 plays a pivotal role in inflammatory processes and induction of the immune response (1, 2) . Two types of IL-I have been described, which display similar activities (3) in spite of their low amino acid sequence homology (26%). Both IL-la and IL-1,/ act on target cells by binding to the same specific plasma membrane receptor proteins, distributed on many cell types (4) . Two types of human receptors have been cloned which belong to the immunoglobulin gene superfamily, both exhibiting three extracellular immunoglobulin-like domains (5) . The main structural difference between the two receptors resides in the length of their cytoplasmic domains, i.e., 213 amino acids in type I receptor and only 29 in type 11 (5) . These two receptors do not function as an heterodimer complex, and the signal seems to be transmitted by type I receptor alone (6) . Therefore, the role of type II receptor at the cell surface remains unclear. IL-1 proinflammatory effects are balanced by IL-I receptor antagonist (IL-IRa).' IL-lRa, which is structurally related to IL-1, binds IL-1 receptors competitively without inducing any biological response (for review see reference 7) . In addition to IL-lRa, IL-1 activity is balanced by soluble forms of its receptors, in analogy to other cytokines such as PDGF and TNF (8, 9) . The soluble type II IL-1 receptor (IL-IsRII) has been detected in normal human plasma (10) , synovial fluids (11) , and supernatants of several human cell lines (12) (13) (14) . Although soluble type I receptor (IL-IsRI) has not been clearly identified to occur naturally, a circulating factor which crossreacts weakly with anti-IL-isRI antibodies has been detected in human normal serum (15) . The IL-1 binding characteristics of this factor are different from those of IL-IsRI, since it binds IL-lRa selectively and with high affinity ( 15 ) . Therefore, since both types of IL-I inhibitor, i.e., IL-lsR and IL-lRa, may simultaneously be present at the inflammatory site, they may interfere with each other's activity. The aim of this study is to elucidate the simultaneous effects of IL-lRa and IL-lsRs on the activation by IL-la and IL- at 100 %sg/ml. In contrast, the monoclonal antibody directed against iL-1RIH did not affectPGE2 production in accordance with previous binding studies (6) . were preincubated together for 1 h at 37°C and then for another hour withIL-I before being added to the cells. After 72 h of incubation, the supernatants were analyzed as described above.
Interstitial collagenase (C'ase) and PGE2. C'ase was measured by ELISA, using specific rabbit polyclonal antisera (19) with a detection limit of 10 ng/ml. PGE2 was measured by a double antibody radioimmunoassay as described previously (17) , using an antiserum to PE2 provided by Dr. M. Seitz (Department of Rheumatology, University Hospital, Bern, Switzerland). The detection limit for PGE2 was 0.5 ng/ml. All inhibitory activity on dermal fibroblasts, inhibiting > 95% of the induced PGE2 and C'ase production (Fig. 1, A and B) . ILIRa also abolished the induced production of PGE2 on synovial cells (Fig. 1 C) , whereas it inhibited the production of C'ase by only 43 and 50% when using IL-la and IL-1,/3 as a stimulus, respectively (Fig. 1 D) . This IL-isRI to revert-the IL-IRa inhibitory activity was particularly pronounced in the production of C'ase induced by IL-1p3 on synovial cells, amounting to > 90% in the presence of both ILIsRI and IL-IRa (Fig. 1 D) . Identical results were obtained when the cells were preincubated with IL-IRa before the addition of IL-I together with IL-IsRI (data not shown). In contrast, the simultaneous presence of IL-IRa and IL-i sRII resulted in a high inhibitory effect on C'ase and PGE2 production by both cell types. Noticeably, C'ase production by synovial cells, hardly inhibited by IL-IRa, was virtually abolished in the simultaneous presence of IL-IRa and IL-IsRII (Fig. 1 D) .
To assess the simultaneous effects of both soluble receptors, experiments were carried out by incubating synovial cells in the presence of both IL-IsRI and IL-isRII by using two different preincubation procedures: (a) the inhibitors were preincubated for 1 h at 370C and then for another hour with the cells before the addition of IL-1 ( Fig. 2 A) ; and (b) the inhibitors were preincubated together for 1 h at 370C and then for another hour with IL-I before being added to the cells (Fig. 2 B) . After 72 h of incubation, the supernatants were analyzed as described above. The representative experiment of Fig. 2 A shows that, when IL-IsRI and IL-IsRII were present simultaneously, additive inhibition was obtained, i.e., PGE2 production induced by IL-la was inhibited to levels obtained with IL-IsRI alone and PGE2 production induced by IL-1p3 was inhibited to levels obtained with IL-1sRII alone. This confirms the results of Fig. 1 which demonstrated that IL-IsRI mainly inhibited IL-la, and IL-IsRII mainly inhibited IL-1,f. When IL-1sRI and IL-1sRII
were added together with IL-lRa, the inhibition of PGE2 production observed in the presence of IL-lRa or IL-lRa and IL1sRII was reverted, particularly when IL-la was the stimulus (Fig. 2 A) . Similar results were obtained by using the second preincubation procedure (Fig. 2 B) , demonstrating that the interactions between IL-1, IL-lsRs, and the cellular receptors are reversible and that they depend on the respective affinities of IL-la, IL-1,3, and IL-IRa for their ligands. Together, the experiments of Figs. 1 and 2 suggest that IL-IsRI and IL-IRa dulled their respective inhibitory activity.
Discussion
The enhancement of the production of PGE2 (i.e., a potent local proinflammatory factor) and C'ase (i.e., a metalloproteinase which plays a major role in extracellular matrix destruction) by IL-1 stimulation of fibroblasts, is an important process in the inflammatory response and the persistence of inflammation in chronic inflammatory diseases. In this study, two types of stroma cells have been used to examine the balance of IL-I stimulation by IL-iRa or IL-IsR. The comparison of these two types of cells shows that synovial cells are slightly modulated by IL-1 stimulation. The production of PGE2 and C'ase was enhanced > 4-fold on synovial cells, whereas on dermal fibroblasts it was enhanced s 10-and 4-fold, respectively. Furthermore, the inhibition obtained with either IL-lsR or IL-iRa was and then for another hour with IL-1 before being added to the cells. After 72 h of incubation, the supernatants were analyzed for the presence of PGE2.
generally less pronounced on synovial cells than on dermal fibroblasts (Fig. 1) ; noticeably, the inhibition of C'ase produc- (Fig. 1, A-C) or even enhance the inhibition (Fig. 1 D) . This is the first observation of the dulling effect of IL-IsRI on the biological inhibitory activity of IL-iRa in the presence or absence of IL-lsRil. Endogenous IL-lRa production plays an important part in disease outcome since neutralizing antibodies to IL-IRa worsen disease (21, 22) . Therefore, because of their ability to interfere with inflammatory mechanisms, IL-iRa as well as IL-IsRI have been used individually as therapeutic agents in various animal models with some efficiency (for review see references 7 and 23). In humans, however, considering the results described in this paper and the binding studies of Svenson et al. (15) , the use of IL-1sRI does not seem to be advisable, since it counters the inhibitory effect of IL-lRa. In contrast, we hypothesize that the simultaneous use of both IL-IRa and IL-1sRII might be mostly beneficial.
